Clinical Trial Update: Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating first-line surufatinib plus serplulimab with standard chemotherapy for advanced solid tumors with neuroendocrine differentiation, inclu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Pancreatic Cancer

Drugs mentioned

• Serplulimab (serplulimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: RenJi Hospital | Conditions: ESCC, Biliary Tract Cancer | Phase 2 | Status: NOT_YET_RECRUITING